)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Synlogic
Synlogic (SYBX) investor relations material
Synlogic Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary11 Aug, 2026
Executive summary
Discontinued lead clinical trial (Synpheny-3 for PKU) in February 2024 after internal review indicated it was unlikely to meet its primary endpoint; not due to safety concerns.
Undertook corporate restructuring, reducing workforce to one full-time employee and engaging consultants to support strategic review and operations.
Entered into a merger agreement with Caldera Therapeutics on July 28, 2026; combined company to focus on Caldera's CLD-423 for IBD and immune-mediated diseases.
Delisted from Nasdaq in January 2026; shares now quoted on OTCID Basic Market.
Financial highlights
Net loss of $0.54 million for Q2 2026, compared to $0.53 million net loss in Q2 2025.
Net income of $0.14 million for the six months ended June 30, 2026, versus a net loss of $0.21 million for the same period in 2025.
Operating expenses for Q2 2026 were $1.01 million, up from $0.78 million in Q2 2025; six-month operating expenses rose to $2.33 million from $1.68 million year-over-year.
Cash and cash equivalents totaled $13.2 million as of June 30, 2026, down from $14.7 million at year-end 2025.
Outlook and guidance
Current cash and cash equivalents expected to fund operations for at least the next 12 months from the filing date.
Expenses anticipated to remain stable in the near term as the company explores strategic alternatives and merger completion.
No expectation of product revenue generation; future funding needs depend on strategic transactions and other factors.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Synlogic
- Q1 2026 net income increased to $0.7M, driven by warrant gains amid ongoing strategic review.SYBX
Q1 2026 - Restructured as a shell after discontinuing clinical programs, with sharply reduced expenses and a $1M net loss.SYBXQ4 2025
- Biopharma seeks $150M shelf offering after pivoting to strategic alternatives post-trial halt.SYBXRegistration Filing
- Amended filing allows flexible securities issuance and updates legal protections for management.SYBXRegistration Filing
- Annual Meeting to vote on director, executive pay, and auditor, with strong governance focus.SYBXProxy Filing
- Net loss narrowed to $2.3M in Q3 2025 amid restructuring and strategic review.SYBXQ3 2025
- Annual Meeting to vote on directors, executive pay, new equity plan, and auditor ratification.SYBXProxy Filing
- Losses narrowed sharply after restructuring and trial discontinuation; strategic review ongoing.SYBXQ2 2025
- Lead program ended, costs cut, and strategic options under review with $19.4M cash on hand.SYBXQ3 2024
Next Synlogic earnings date
Q3 202619 Nov, 2026
Synlogic
Next Synlogic earnings date
Q3 202619 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Synlogic Inc. is a biotechnology company focused on developing synthetic biotic medicines, which are engineered living organisms designed to treat metabolic and other diseases. The company’s platform uses genetically modified bacteria to deliver therapeutic effects within the human body, targeting diseases such as phenylketonuria (PKU) and other metabolic disorders. Synlogic’s approach aims to address unmet medical needs through innovative treatments that leverage the power of synthetic biology. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.